Prognostic value of von Willebrand factor for patients with atrial fibrillation: a meta-analysis of prospective cohort studies

2019 ◽  
Vol 96 (1135) ◽  
pp. 267-276 ◽  
Author(s):  
Yuan-Zheng Ye ◽  
Ya-Fei Chang ◽  
Bao-Zhu Wang ◽  
Yi-Tong Ma ◽  
Xiang Ma
Keyword(s):  
Atrial Fibrillation ◽  
Cohort Studies ◽  
Von Willebrand Factor ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Cardiovascular Death ◽  
Cochrane Library ◽  
Prospective Cohort Studies ◽  
Von Willebrand ◽  
Willebrand Factor

BackgroundIt is unknown whether an abnormal level of von Willebrand factor (vWF) is correlated with the prognosis of patients with atrial fibrillation (AF) and current findings are controversial. This meta-analysis aimed to evaluate the association between vWF levels and the clinical prognosis of patients with AF.MethodsWe searched prospective cohort studies on PubMed, Embase, Web of Science, Cochrane Library and WanFang databases for vWF and adverse events of AF from inception of the databases to July 2019. The risk ratios of all-cause death, cardiovascular death, major adverse cardiac events (MACE), stroke and bleeding prognosis in patients with AF were analysed using a fixed-effects model or random-effects model, and all included studies were evaluated with heterogeneity and publication bias analysis.ResultsTwelve studies which included 7449 patients with AF were used in the meta-analysis. The average age was 71.3 years and the average follow-up time was 3.38 years. The analysis found that high vWF levels were associated with increased risks of all-cause death (RR 1.56; 95% CI 1.16 to 2.11, p=0.00400), cardiovascular death (RR 1.91; 95% CI 1.20 to 3.03, p=0.00600), MACE (RR 1.83; 95% CI 1.28 to 2.62, p=0.00090), stroke (RR 1.69; 95% CI 1.08 to 2.64, p=0.02000) and bleeding (RR 2.01; 95% CI 1.65 to 2.45, p<0.00001) in patients with AF.ConclusionsvWF is a risk factor for poor prognosis of AF, and patients with higher vWF levels have a higher risk of all-cause death, cardiovascular death, MACE, stroke and bleeding.

scholarly journals Association between maternal vitamin D deficiency and small for gestational age: evidence from a meta-analysis of prospective cohort studies

BMJ Open ◽  
2017 ◽  
Vol 7 (8) ◽  
pp. e016404 ◽  
Author(s):  
Yao Chen ◽  
Beibei Zhu ◽  
Xiaoyan Wu ◽  
Si Li ◽  
Fangbiao Tao
Keyword(s):  
Vitamin D ◽  
Cohort Studies ◽  
Vitamin D Deficiency ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Maternal Vitamin ◽  
Prospective Cohort Studies

ObjectiveTo determine whether maternal vitamin D deficiency during pregnancy is associated with small for gestational age (SGA).MethodsA comprehensive literature search of PubMed, the Cochrane Library, Embase, and the Elsevier ScienceDirect library was conducted to identify relevant articles reporting prospective cohort studies in English, with the last report included published in February 2017. Pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were used to evaluate the correlation in a random effects model.ResultsA total of 13 cohort studies were included in this meta-analysis with a sample of 28 285 individuals from seven countries. The pooled overall OR for babies born SGA was 1.588 (95%CI 1.138 to 2.216; p<0.01) for women with vitamin D deficiency. The prevalence of vitamin D deficiency during pregnancy varied from 13.2% to 77.3%. Subgroup analyses identified no significant differences in the association between vitamin D deficiency and SGA based on study quality, gestational week during which blood sampling was performed, cut-off vitamin D levels, sample size, adjustment for critical confounders and method for measuring vitamin D.ConclusionThis meta-analysis suggests that vitamin D deficiency is associated with an increased risk of SGA.

Breastfeeding and Atopic Dermatitis Risk: A Systematic Review and Meta-Analysis of Prospective Cohort Studies

Dermatology ◽  
2019 ◽  
Vol 236 (4) ◽  
pp. 345-360 ◽  
Author(s):  
Bingjiang Lin ◽  
Ru Dai ◽  
Lingyi Lu ◽  
Xin Fan ◽  
Yingzhe Yu
Keyword(s):  
Atopic Dermatitis ◽  
Cohort Studies ◽  
Exclusive Breastfeeding ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Protective Function ◽  
Prospective Cohort Studies ◽  
Weak Evidence ◽  
Comprehensive Search

Objectives: The effect of breastfeeding on atopic dermatitis (AD) remains controversial. To determine the association ­between breastfeeding and AD, we conducted an updated meta-analysis of prospective cohort studies. Methods: A comprehensive search of PubMed, EMBASE, MEDLINE and Cochrane Library was conducted. Studies meeting the predetermined criteria were evaluated by 2 authors independently. The pooled relative risk (RR) adjusted for confounders with its 95% CI was calculated by a random-effects model. Heterogeneity was explored by subgroup analysis and meta-regression. Results: A total of 27 studies were included for meta-analysis. The pooled estimates for the effect of total and exclusive breastfeeding on AD were 1.01 (95% CI 0.93–1.10) and 0.99 (95% CI 0.88–1.11), respectively. Heterogeneity was substantial across studies (total: p < 0.01 or I2 = 65.2%; exclusive: p < 0.01 or I2 = 72.3%). There was a weak evidence for a protective effect of breastfeeding against AD in cohorts with atopic heredity (total: RR 0.85, 95% CI 0.74–0.98; exclusive: RR 0.83, 95% CI 0.70–0.97). In cohorts without atopic heredity, the effect shifted to the risk side when limited to exclusive breastfeeding (RR 1.19, 95% CI 1.02–1.40) while it dropped towards null when limited to total breastfeeding (RR 1.11, 95% CI 0.94–1.31). Conclusions: There is no association between AD and breastfeeding, regardless of total or exclusive breastfeeding patterns. There is some evidence for a protective function of exclusive and total breastfeeding in a cohort with atopic heredity. The effect shifts to the risk side in cohorts without atopic heredity. However, these findings should be interpreted with caution because heterogeneity is evident.

Cardiovascular Mortality after Venous Thromboembolism: A Meta-Analysis of Prospective Cohort Studies

2021 ◽  
Author(s):  
Steve Raoul Noumegni ◽  
Thomas Grangereau ◽  
Arzu Demir ◽  
Luc Bressollette ◽  
Francis Couturaud ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Cardiovascular Diseases ◽  
General Population ◽  
Cohort Studies ◽  
Incidence Rate ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Cardiovascular Death ◽  
Prospective Cohort Studies ◽  
The Impact

AbstractMany studies from current literature show that cardiovascular diseases in patients with venous thromboembolism (VTE) are more frequent than in the general population without VTE. However, data summarizing the impact of cardiovascular diseases on mortality of patients with VTE are lacking. In this systematic review and meta-analysis, we aimed to determine the frequency and incidence rate of cardiovascular death in patients with VTE. MEDLINE and EMBASE were searched from January 1, 2000 to February 28, 2021. Eligible studies were observational prospective cohort studies including patients with VTE and reporting all causes of death. Cardiovascular death was defined as deaths that result from new or recurrent pulmonary embolism, death due to acute myocardial infarction, sudden cardiac death or heart failure, death due to stroke, death due to cardiovascular procedures or hemorrhage, death due to ruptured aortic aneurysm or aortic dissection and death due to other cardiovascular causes. Random-effect models meta-analysis served to determine all pooled effect size of interest with their 95% confidence interval (CI). Thirteen observational studies enrolling 22,251 patients were identified and included. The mean/median age varied between 49 and 75 years. The proportion of men ranged from 38.3 to 53.2%. The overall pooled frequency of cardiovascular death in patients with VTE was 3.9% (95% CI: 2.5–5.6%), while the overall pooled frequency of all-cause mortality was 12.0% (95% CI: 9.1–15.4%). The pooled proportion of cardiovascular death among all causes of deaths in patients with VTE was 35.2% (95% CI: 22.2–49.3%). The pooled incidence rate of cardiovascular death was 1.92 per 100 patient-years (95% CI: 0–4.1). The frequency of cardiovascular death in patients with VTE was significantly higher than in patients without VTE (risk ratio: 3.85, 95% CI: 2.75–5.39). Based on this updated meta-analysis from 13 prospective cohort studies, cardiovascular death in patients with VTE is more frequent than in the general population without VTE.

scholarly journals Adiponectin and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies

2019 ◽  
Vol 39 (6) ◽  
Author(s):  
Ying Guo ◽  
Lixin Liu ◽  
Jianjun Wang
Keyword(s):  
Atrial Fibrillation ◽  
General Population ◽  
Cohort Studies ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Serum Adiponectin ◽  
Prospective Cohort Studies ◽  
Subgroup Analyses ◽  
New Onset

Abstract Background: Adiponectin has been suggested as a marker of many cardiovascular diseases. However, the association between serum adiponectin and incidence of atrial fibrillation (AF) in general population remains unclear. A meta-analysis was performed to systematically evaluate the potential influence of serum adiponectin at baseline on the incidence of AF during follow-up in general population. Methods: Prospective cohort studies were identified via electronic search of PubMed and Embase databases. A randomized effect model was applied to combine the results. Predefined subgroup analyses were performed to evaluate the influence of study characteristics on the association between baseline adiponectin and risk of new-onset AF. Results: Six cohort studies with 18558 community-derived participants were included, and 3165 AF cases were developed with a mean follow-up duration of up to 22 years. Meta-analysis showed that higher baseline circulating adiponectin was significantly associated with higher risk of new-onset AF during follow-up (hazard ratio [HR]: 1.17, 95% confidence interval [CI]: 1.08–1.27, P<0.001, I2 = 52%). Subgroup analyses showed that the association between adiponectin and new-onset AF was significant in studies with mean follow-up duration over 10 years (five cohorts, HR = 1.22, P<0.001), but not in that with a follow-up duration < 10 years (one cohort, HR = 0.95, P=0.51; P for subgroup difference = 0.002). Conclusions: Higher circulating adiponectin at baseline may be an independent risk factor for the development of new-onset AF during follow-up, particularly in cohort studies with longer follow-up durations.

scholarly journals Important food sources of fructose-containing sugars and incident gout: a systematic review and meta-analysis of prospective cohort studies

BMJ Open ◽  
2019 ◽  
Vol 9 (5) ◽  
pp. e024171 ◽  
Author(s):  
Sabrina Ayoub-Charette ◽  
Qi Liu ◽  
Tauseef A Khan ◽  
Fei Au-Yeung ◽  
Sonia Blanco Mejia ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cohort Studies ◽  
Prospective Cohort ◽  
Fruit Juice ◽  
Meta Analysis ◽  
Food Sources ◽  
Cochrane Library ◽  
Fruit Intake ◽  
Important Food ◽  
Prospective Cohort Studies

ObjectiveSugar-sweetened beverages (SSBs) are associated with hyperuricaemia and gout. Whether other important food sources of fructose-containing sugars share this association is unclear.DesignTo assess the relation of important food sources of fructose-containing sugars with incident gout and hyperuricaemia, we conducted a systematic review and meta-analysis of prospective cohort studies.MethodsWe searched MEDLINE, Embase and the Cochrane Library (through 13 September 2017). We included prospective cohort studies that investigated the relationship between food sources of sugar and incident gout or hyperuricaemia. Two independent reviewers extracted relevant data and assessed the risk of bias. We pooled natural-log transformed risk ratios (RRs) using the generic inverse variance method with random effects model and expressed as RR with 95% confidence intervals (CIs). The overall certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation system.ResultsWe identified three studies (1 54 289 participants, 1761 cases of gout), comparing the highest with the lowest level of exposure for SSBs, fruit juices and fruits. No reports were found reporting incident hyperuricaemia. Fruit juice and SSB intake showed an adverse association (fruit juice: RR=1.77, 95% CI 1.20 to 2.61; SSB: RR=2.08, 95% CI 1.40 to 3.08), when comparing the highest to lowest intake of the most adjusted models. There was no significant association between fruit intake and gout (RR 0.85, 95% CI 0.63 to 1.14). The strongest evidence was for the adverse association with SSB intake (moderate certainty), and the weakest evidence was for the adverse association with fruit juice intake (very low certainty) and lack of association with fruit intake (very low certainty).ConclusionThere is an adverse association of SSB and fruit juice intake with incident gout, which does not appear to extend to fruit intake. Further research is needed to improve our estimates.Trial registration numberNCT02702375; Results.

scholarly journals Height and Risk of Hip Fracture: A Meta-Analysis of Prospective Cohort Studies

2016 ◽  
Vol 2016 ◽  
pp. 1-8
Author(s):  
Zhihong Xiao ◽  
Dong Ren ◽  
Wei Feng ◽  
Yan Chen ◽  
Wusheng Kan ◽  
...  
Keyword(s):  
Hip Fracture ◽  
Cohort Studies ◽  
Prospective Cohort ◽  
Web Of Science ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Response Analysis ◽  
Prospective Cohort Studies ◽  
Increased Risk ◽  
The Cochrane Library

The association between height and risk of hip fracture has been investigated in several studies, but the evidence is inconclusive. We therefore conducted this meta-analysis of prospective cohort studies to explore whether an association exists between height and risk of hip fracture. We searched PubMed and EMBASE, Web of Science, and the Cochrane Library for studies of height and risk of hip fracture up to February 16, 2016. The random-effects model was used to combine results from individual studies. Seven prospective cohort studies, with 7,478 incident hip fracture cases and 907,913 participants, were included for analysis. The pooled relative risk (RR) was 1.65 (95% confidence interval (CI): 1.26–2.16) comparing the highest with the lowest category of height. Result from dose-response analysis suggested a linear association between height and hip fracture risk (P-nonlinearity = 0.0378). The present evidence suggests that height is positively associated with increased risk of hip fracture. Further well-designed cohort studies are needed to confirm the present findings in other ethnicities.

Sign in / Sign up

Export Citation Format

Share Document